JPWO2018009624A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018009624A5 JPWO2018009624A5 JP2019500446A JP2019500446A JPWO2018009624A5 JP WO2018009624 A5 JPWO2018009624 A5 JP WO2018009624A5 JP 2019500446 A JP2019500446 A JP 2019500446A JP 2019500446 A JP2019500446 A JP 2019500446A JP WO2018009624 A5 JPWO2018009624 A5 JP WO2018009624A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- heteromultimer
- heteromultimers
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 750
- 229920001184 polypeptide Polymers 0.000 claims description 740
- 101710027366 ACVRL1 Proteins 0.000 claims description 149
- 102100009705 ENG Human genes 0.000 claims description 112
- 108010036395 Endoglin Proteins 0.000 claims description 112
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102100007311 BMP10 Human genes 0.000 claims description 3
- 101700058635 BMP10 Proteins 0.000 claims description 3
- 102100003277 GDF2 Human genes 0.000 claims description 3
- 101700046122 GDF2 Proteins 0.000 claims description 3
- 102000037240 fusion proteins Human genes 0.000 claims 19
- 108020001507 fusion proteins Proteins 0.000 claims 19
- 239000000833 heterodimer Substances 0.000 claims 18
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000003899 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 738
- 230000027455 binding Effects 0.000 description 563
- 239000003446 ligand Substances 0.000 description 408
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 325
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 325
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 323
- 238000004166 bioassay Methods 0.000 description 233
- 101710026725 ACVR1C Proteins 0.000 description 165
- 102100000004 ACVR1C Human genes 0.000 description 165
- 230000002401 inhibitory effect Effects 0.000 description 158
- 230000011664 signaling Effects 0.000 description 158
- 102100000002 ACVRL1 Human genes 0.000 description 147
- 101710024841 BMPR1B Proteins 0.000 description 147
- 102100000003 ACVR1B Human genes 0.000 description 145
- 101710026724 ACVR1B Proteins 0.000 description 145
- 102100003993 TGFBR1 Human genes 0.000 description 143
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 143
- 102100003919 ACVR1 Human genes 0.000 description 134
- 101700044023 ACVR1 Proteins 0.000 description 134
- 102100014323 BMPR1A Human genes 0.000 description 132
- 101710024842 BMPR1A Proteins 0.000 description 132
- 102100014282 BMPER Human genes 0.000 description 123
- 101700066241 BMPER Proteins 0.000 description 123
- 101700067747 CFC1 Proteins 0.000 description 104
- 102100003606 CFC1 Human genes 0.000 description 104
- 102100008284 TGFBR3 Human genes 0.000 description 102
- 108010079292 betaglycan Proteins 0.000 description 102
- 101700073629 TDGF1 Proteins 0.000 description 95
- 102100005491 TDGF1 Human genes 0.000 description 95
- 101700086310 KCP Proteins 0.000 description 94
- 102100003605 CFC1B Human genes 0.000 description 93
- 101700049371 CFC1B Proteins 0.000 description 93
- 101700040623 CRIM1 Proteins 0.000 description 88
- 102100010673 BAMBI Human genes 0.000 description 81
- 108060000859 BAMBI Proteins 0.000 description 81
- 210000004027 cells Anatomy 0.000 description 80
- 102000007374 Smad Proteins Human genes 0.000 description 77
- 108010007945 Smad Proteins Proteins 0.000 description 77
- 238000000338 in vitro Methods 0.000 description 77
- 230000000875 corresponding Effects 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 108010059616 Activins Proteins 0.000 description 15
- 102000000213 Hemojuvelin Human genes 0.000 description 15
- 108050008605 Hemojuvelin Proteins 0.000 description 15
- 102100008240 INHBE Human genes 0.000 description 15
- 239000000488 activin Substances 0.000 description 15
- 239000000539 dimer Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 7
- -1 Cryptic Proteins 0.000 description 6
- 102100019916 MSTN Human genes 0.000 description 5
- 102100014260 MUSK Human genes 0.000 description 5
- 101700018763 MUSK Proteins 0.000 description 5
- 108010056852 Myostatin Proteins 0.000 description 5
- 102100005377 BMP2 Human genes 0.000 description 4
- 101700000123 BMP2 Proteins 0.000 description 4
- 102100015886 BMP4 Human genes 0.000 description 4
- 101700005069 BMP4 Proteins 0.000 description 4
- 102100003272 GDF11 Human genes 0.000 description 4
- 101700065866 GDF11 Proteins 0.000 description 4
- 102100003273 GDF15 Human genes 0.000 description 4
- 102100010135 GDF6 Human genes 0.000 description 4
- 101700040898 GDF6 Proteins 0.000 description 4
- 108060008201 GDNF Proteins 0.000 description 4
- 102100000369 GDNF Human genes 0.000 description 4
- 102000024920 TGF-beta family Human genes 0.000 description 3
- 108091020535 TGF-beta family Proteins 0.000 description 3
- 102100014320 TGFB1 Human genes 0.000 description 3
- 102100014858 AMH Human genes 0.000 description 2
- 102100012672 ARTN Human genes 0.000 description 2
- 101700061329 ARTN Proteins 0.000 description 2
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
- 102100007312 BMP15 Human genes 0.000 description 2
- 101700009099 BMP15 Proteins 0.000 description 2
- 102100005375 BMP3 Human genes 0.000 description 2
- 101700001588 BMP3 Proteins 0.000 description 2
- 102100015881 BMP5 Human genes 0.000 description 2
- 101700018737 BMP5 Proteins 0.000 description 2
- 102100015880 BMP6 Human genes 0.000 description 2
- 101700086945 BMP6 Proteins 0.000 description 2
- 102100015882 BMP7 Human genes 0.000 description 2
- 101700060441 BMP7 Proteins 0.000 description 2
- 101700021530 GDF15 Proteins 0.000 description 2
- 101700054531 GDF3 Proteins 0.000 description 2
- 102100003278 GDF3 Human genes 0.000 description 2
- 102100003274 GDF5 Human genes 0.000 description 2
- 101700016442 GDF5 Proteins 0.000 description 2
- 102100010137 GDF7 Human genes 0.000 description 2
- 101700021567 GDF7 Proteins 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 102100015653 NRTN Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 108060007065 RMC1 Proteins 0.000 description 2
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 108010023079 activin B Proteins 0.000 description 2
- 101700080346 artM Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 102100009714 ACVR2A Human genes 0.000 description 1
- 102100010622 ACVR2B Human genes 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 101710037955 GARS1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 102000017481 Repulsive guidance molecule Human genes 0.000 description 1
- 108050005592 Repulsive guidance molecule Proteins 0.000 description 1
- 102100017951 SMAD1 Human genes 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700041213 TGFB1 Proteins 0.000 description 1
- 102100003994 TGFBR2 Human genes 0.000 description 1
- 101710011270 TGFBR2 Proteins 0.000 description 1
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010057429 activin receptor type II-A Proteins 0.000 description 1
- 108010057453 activin receptor type II-B Proteins 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 230000001965 increased Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022144508A JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Tgfベータスーパーファミリーホモ多量体およびその使用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662359614P | 2016-07-07 | 2016-07-07 | |
US62/359,614 | 2016-07-07 | ||
US201662404670P | 2016-10-05 | 2016-10-05 | |
US62/404,670 | 2016-10-05 | ||
PCT/US2017/040849 WO2018009624A1 (en) | 2016-07-07 | 2017-07-06 | Tgf-beta superfamily heteromultimers and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022144508A Division JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Tgfベータスーパーファミリーホモ多量体およびその使用 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2019527547A JP2019527547A (ja) | 2019-10-03 |
JP2019527547A5 JP2019527547A5 (pl) | 2020-08-13 |
JPWO2018009624A5 true JPWO2018009624A5 (pl) | 2022-09-22 |
JP7159148B2 JP7159148B2 (ja) | 2022-10-24 |
Family
ID=60913181
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019500446A Active JP7159148B2 (ja) | 2016-07-07 | 2017-07-06 | Tgfベータスーパーファミリーホモ多量体およびその使用 |
JP2022144508A Pending JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Tgfベータスーパーファミリーホモ多量体およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022144508A Pending JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Tgfベータスーパーファミリーホモ多量体およびその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200071382A1 (pl) |
EP (1) | EP3481860A4 (pl) |
JP (2) | JP7159148B2 (pl) |
AU (2) | AU2017293778B2 (pl) |
CA (1) | CA3029890A1 (pl) |
WO (1) | WO2018009624A1 (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームi型およびii型受容体融合タンパク質およびその使用 |
WO2016164503A1 (en) | 2015-04-06 | 2016-10-13 | Acceleron Pharma Inc. | Alk7:actriib heteromultimers and uses thereof |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
CN110036025B (zh) | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
KR20190075078A (ko) | 2016-10-05 | 2019-06-28 | 악셀레론 파마 인코포레이티드 | ALK4:ActRIIB 이형다량체 및 이의 용도 |
WO2019213442A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
AU2019285299A1 (en) * | 2018-06-15 | 2020-12-03 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2827188C (en) * | 2011-03-17 | 2020-02-11 | Itai Benhar | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
CN108178789B (zh) * | 2011-04-20 | 2021-11-02 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
US20140193425A1 (en) * | 2012-10-05 | 2014-07-10 | Acceleron Pharma, Inc. | Treatment of cancer with alk1 antagonists |
EP3851118A1 (en) * | 2013-10-25 | 2021-07-21 | Acceleron Pharma Inc. | Endoglin peptides to treat fibrotic diseases |
WO2015147908A1 (en) * | 2014-03-28 | 2015-10-01 | Acceleron Pharma, Inc. | Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer |
WO2015160940A1 (en) * | 2014-04-15 | 2015-10-22 | President And Fellows Of Harvard College | Bi-specific agents |
-
2017
- 2017-07-06 EP EP17824864.7A patent/EP3481860A4/en active Pending
- 2017-07-06 AU AU2017293778A patent/AU2017293778B2/en active Active
- 2017-07-06 WO PCT/US2017/040849 patent/WO2018009624A1/en unknown
- 2017-07-06 US US16/315,338 patent/US20200071382A1/en not_active Abandoned
- 2017-07-06 JP JP2019500446A patent/JP7159148B2/ja active Active
- 2017-07-06 CA CA3029890A patent/CA3029890A1/en active Pending
-
2022
- 2022-03-08 AU AU2022201603A patent/AU2022201603A1/en not_active Abandoned
- 2022-09-12 JP JP2022144508A patent/JP2022172479A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7203807B2 (ja) | シングルアームi型およびii型受容体融合タンパク質およびその使用 | |
JP7037363B2 (ja) | Tgfベータスーパーファミリーi型およびii型受容体ヘテロ多量体およびその使用 | |
JP7280182B2 (ja) | バリアントActRIIBタンパク質およびその使用 | |
JP7159148B2 (ja) | Tgfベータスーパーファミリーホモ多量体およびその使用 | |
JP7219705B2 (ja) | ALK4:ActRIIBヘテロ多量体およびその使用 | |
EP3293198B1 (en) | Variants derived from actriib and uses therefor | |
EP3929211A1 (en) | Alk4:actriib heteromultimers and uses thereof | |
JP7097354B2 (ja) | Tgf-ベータスーパーファミリーi型およびii型受容体ヘテロ多量体ならびにその使用 | |
JP2018510637A (ja) | フォリスタチン関連融合タンパク質およびその使用 | |
JPWO2018009624A5 (pl) | ||
JP2023528709A (ja) | バリアントactriibタンパク質およびその使用 | |
EP3735418A1 (en) | Single-arm co-receptor fusion proteins and uses thereof |